Oppenheimer Asset Management’s CVS Health CVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $37.7M | Buy |
524,266
+21,970
| +4% | +$1.69M | 0.43% | 51 |
|
|
2025
Q4 | $39.9M | Sell |
502,296
-7,726
| -2% | -$609K | 0.49% | 44 |
|
|
2025
Q3 | $38.5M | Buy |
510,022
+5,771
| +1% | +$396K | 0.42% | 49 |
|
|
2025
Q2 | $34.8M | Sell |
504,251
-34,090
| -6% | -$2.24M | 0.4% | 51 |
|
|
2025
Q1 | $36.5M | Buy |
538,341
+102,470
| +24% | +$6.13M | 0.45% | 44 |
|
|
2024
Q4 | $19.6M | Sell |
435,871
-12,452
| -3% | -$699K | 0.24% | 107 |
|
|
2024
Q3 | $28.2M | Buy |
448,323
+24,285
| +6% | +$1.42M | 0.34% | 64 |
|
|
2024
Q2 | $25M | Buy |
424,038
+204,718
| +93% | +$12.8M | 0.32% | 70 |
|
|
2024
Q1 | $17.5M | Sell |
219,320
-23,309
| -10% | -$1.78M | 0.26% | 88 |
|
|
2023
Q4 | $19.2M | Buy |
242,629
+36,726
| +18% | +$2.61M | 0.27% | 82 |
|
|
2023
Q3 | $14.4M | Sell |
205,903
-4,262
| -2% | -$302K | 0.22% | 107 |
|
|
2023
Q2 | $14.5M | Buy |
210,165
+8,612
| +4% | +$613K | 0.21% | 114 |
|
|
2023
Q1 | $15M | Sell |
201,553
-1,042
| -0.5% | -$87.4K | 0.23% | 107 |
|
|
2022
Q4 | $18.9M | Sell |
202,595
-23,343
| -10% | -$2.25M | 0.3% | 77 |
|
|
2022
Q3 | $21.5M | Buy |
225,938
+2,254
| +1% | +$223K | 0.38% | 60 |
|
|
2022
Q2 | $20.7M | Sell |
223,684
-17,085
| -7% | -$1.67M | 0.35% | 66 |
|
|
2022
Q1 | $24.4M | Sell |
240,769
-4,228
| -2% | -$444K | 0.35% | 65 |
|
|
2021
Q4 | $25.3M | Buy |
244,997
+9,011
| +4% | +$833K | 0.34% | 64 |
|
|
2021
Q3 | $20M | Sell |
235,986
-5,455
| -2% | -$457K | 0.28% | 79 |
|
|
2021
Q2 | $20.1M | Buy |
241,441
+2,465
| +1% | +$202K | 0.29% | 80 |
|
|
2021
Q1 | $18M | Buy |
238,976
+39,994
| +20% | +$2.91M | 0.28% | 84 |
|
|
2020
Q4 | $13.6M | Sell |
198,982
-34,391
| -15% | -$2.24M | 0.23% | 108 |
|
|
2020
Q3 | $13.6M | Sell |
233,373
-21,940
| -9% | -$1.37M | 0.26% | 94 |
|
|
2020
Q2 | $16.6M | Sell |
255,313
-14,413
| -5% | -$908K | 0.34% | 64 |
|
|
2020
Q1 | $16M | Sell |
269,726
-32,688
| -11% | -$2.18M | 0.39% | 57 |
|
|
2019
Q4 | $22.5M | Sell |
302,414
-10,766
| -3% | -$756K | 0.47% | 34 |
|
|
2019
Q3 | $19.8M | Buy |
313,180
+44,891
| +17% | +$2.66M | 0.44% | 37 |
|
|
2019
Q2 | $14.6M | Buy |
268,289
+118,460
| +79% | +$6.38M | 0.32% | 71 |
|
|
2019
Q1 | $8.08M | Buy |
149,829
+137,539
| +1,119% | +$8.49M | 0.18% | 139 |
|
|
2018
Q4 | $806K | Buy |
+12,290
| New | +$917K | 0.02% | 629 |
|
|
2018
Q2 | – | Sell |
-5,599
| Closed | -$348K | – | 1141 |
|
|
2018
Q1 | $348K | Sell |
5,599
-19,768
| -78% | -$1.42M | 0.01% | 890 |
|
|
2017
Q4 | $2.06M | Hold |
25,367
| – | – | 0.05% | 369 |
|
|
2017
Q3 | $2.06M | Sell |
25,367
-8,098
| -24% | -$641K | 0.05% | 371 |
|
|
2017
Q2 | $2.69M | Sell |
33,465
-10,679
| -24% | -$843K | 0.07% | 290 |
|
|
2017
Q1 | $3.47M | Buy |
+44,144
| New | +$3.52M | 0.1% | 238 |
|
Other funds holding CVS
VCM
VPM
Oppenheimer Asset Management's CVS Position: Q1 2026 in Review
Oppenheimer Asset Management increased its CVS Health (CVS) stake by 4.4% in Q1 2026, buying an estimated $1.69M and bringing the position to 524,266 shares worth $37.7M. The position accounts for 0.43% of the portfolio, ranked #51.
Oppenheimer Asset Management first reported a position in CVS in Q1 2017 and has held it in 35 quarters since. The position peaked at $39.9M in Q4 2025. 1,865 funds tracked by Wall St. Rank hold CVS as of Q1 2026.
- Oppenheimer Asset Management held 524,266 shares of CVS Health worth $37.7M as of Q1 2026.
- Oppenheimer Asset Management bought 21,970 CVS Health shares in Q1 2026, an estimated $1.69M.
- CVS Health made up 0.43% of Oppenheimer Asset Management's portfolio in Q1 2026, its #51 holding.
- Oppenheimer Asset Management first reported a position in CVS Health in Q1 2017 and has held it in 35 quarters since.
- Oppenheimer Asset Management's CVS Health position peaked at $39.9M in Q4 2025.
- 1,865 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.